Skip to main content

Slow-Release Isosorbide-5-Mononitrate for the Treatment of Angina Pectoris: Duration of Effects

  • Conference paper
Mononitrates

Part of the book series: International Boehringer Mannheim Symposia ((BOEHRINGER))

Abstract

Isosorbide dinitrate (ISDN) is widely used for the treatment of angina pectoris and has been shown to prolong exercise tolerance during acute and sustained therapy [1–8]. However, ISDN is poorly bioavailable after oral intake, and a marked inter-individual variation in plasma ISDN concentrations has been reported after oral doses during both acute and chronic therapy [4]. After oral ingestion, ISDN is rapidly metabolized into 2- and 5-mononitrates, both of which are biologically active. Now commercially available in Europe, isosorbide-5-mononitrate (IS-5-MN) has a half-life of 4–6 h and is almost 100% bioavailable after oral ingestion [9]. The latter makes this compound pharmacokinetically more desirable than its parent compound ISDN. Furthermore, a slow-release formulation of IS-5-MN providing high plasma levels for up to 24 h is now available which should theoretically offer advantages by exerting antianginal effects over a prolonged period of time.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Glancy DL, Ritcher MA, Ellis EV, Johnson W (1977) Effect of swallowed isosorbide dinitrate on blood pressure, heart rate, and exercise capacity in patients with coronary artery disease. Am J Med 62:39

    Article  PubMed  CAS  Google Scholar 

  2. Danahy DT, Aronow WS (1977) Hemodynamic and antianginal effects of high-dose oral isosorbide dinitrate after chronic use. Circulation 56:205

    PubMed  CAS  Google Scholar 

  3. Danahy DT, Burwell DT, Aronow WS, Prakash R (1977) Sustained hemodynamic and antianginal effects of high oral dose isosorbide dinitrate. Circulation 55:381

    PubMed  CAS  Google Scholar 

  4. Thadani U, Fung H-L, Darke AC, Parker JO (1982) Oral isosorbide dinitrate in angina pectoris: comparison of duration of action and dose response relationship during acute and sustained therapy. Am J Cardiol 219:411

    Article  Google Scholar 

  5. Thadani U (1984) Nitrates for angina pectoris: a critical review of therapeutic efficacy and tolerance. Herz 9:123

    PubMed  CAS  Google Scholar 

  6. Lee G, Mason DT, Amsterdam EA, Miller RR, Demaria AM (1978) Antianginal efficacy of oral therapy with isosorbide dinitrate capsules: prolonged benefit shown by exercise testing in patients with ischemic heart disease. Chest 73:327

    Article  PubMed  CAS  Google Scholar 

  7. Rudolph W, Blasini R, Froer KL, Brügmann U, Mannes A, Hall D (1981) Effects of acute and chronic administration of isosorbide dinitrate, sustained-release form, in patients with angina pectoris. In: Lichtlen PR, Engel H-J, Schrey A, Swan HJC (eds) Nitrates III. Springer, Berlin Heidelberg New York, p 75

    Chapter  Google Scholar 

  8. Schneider W, Wietschoreck, Bussmann WD, Kaltenbach M (1983) Sustained antianginal efficacy of high-dose isosorbide dinitrate in patients with coronary heart disease. Z Kardiol 72 [Suppl 3]:259

    PubMed  Google Scholar 

  9. Chasseaud LF, Taylor T (1981) Pharmacokinetics of isosorbide-5-mononitrate. In: Kaltenbach, Bussmann, Schrey (eds) Mononitrate workshop. Wolf, Munich, p 12

    Google Scholar 

  10. Thadani U, Hamilton S, Teague S, Brady D, White B (to be published) Circulatory and antianginal effects of isosorbide-5-mononitrate: slow-release formulation in angina pectoris.

    Google Scholar 

  11. Parker JO, Vankoughnett KA, Fung H-L (1984) Transdermal isosorbide dinitrate in angina pectoris: effects of acute and sustained therapy. Am J Cardiol 54:8

    Article  PubMed  CAS  Google Scholar 

  12. Tauchert M, Jansen W, Osterspey A, Fuchs M, Hombach V, Hilger HH (1983) Dose dependence of tolerance during treatment with mononitrates. Z Kardiol 72 [Suppl 3]:218

    PubMed  Google Scholar 

Download references

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 1985 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Thadani, U., Hamilton, S., Teague, S., Brady, D., White, B. (1985). Slow-Release Isosorbide-5-Mononitrate for the Treatment of Angina Pectoris: Duration of Effects. In: Cohn, J.N., Rittinghausen, R. (eds) Mononitrates. International Boehringer Mannheim Symposia. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-70234-1_22

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-70234-1_22

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-15107-4

  • Online ISBN: 978-3-642-70234-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics